Ulcerative Proctitis Pipeline Insight
DelveInsight’s, “Ulcerative Proctitis - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Ulcerative Proctitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Ulcerative Proctitis Understanding
Ulcerative Proctitis: Overview
Ulcerative Proctitis is a mild form of ulcerative colitis, a chronic inflammatory bowel disease (IBD) consisting of fine ulcerations in the inner mucosal lining of the large intestine that do not penetrate the bowel muscle wall. In this form of colitis, the inflammation begins at the rectum, and spreads no more than about 20 cm (7-8″) into the colon. About 25-30% of those diagnosed with ulcerative colitis might actually have Ulcerative Proctitis. The cause of Ulcerative Proctitis is undetermined but there is considerable research evidence to suggest that interactions between environmental factors, intestinal flora, immune dysregulation, and genetic predisposition are responsible. It is unclear why the inflammation is limited to the rectum. There is a slightly increased risk for those who have a family member with the condition.
"Ulcerative Proctitis - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ulcerative Proctitis pipeline landscape is provided which includes the disease overview and Ulcerative Proctitis treatment guidelines. The assessment part of the report embraces, in depth Ulcerative Proctitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ulcerative Proctitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Ulcerative Proctitis R&D. The therapies under development are focused on novel approaches to treat/improve Ulcerative Proctitis.
Ulcerative Proctitis Emerging Drugs Chapters
This segment of the Ulcerative Proctitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Ulcerative Proctitis Emerging Drugs
FW 424: First Wave Bio
A rectal formulation of niclosamide, designated FW 424, is being developed by First Wave Bio, for the treatment of ulcerative colitis and Ulcerative Proctitis. Currently, it is in Phase I/II stage of clinical trial evaluation.
Budesonide suppository: Dr Falk Pharma
A rectal suppository formulation of budesonide (2mg and 4mg) is being developed by Dr. Falk Pharma for the treatment of inflammatory bowel diseases.
Further product details are provided in the report……..
Ulcerative Proctitis: Therapeutic Assessment
This segment of the report provides insights about the different Ulcerative Proctitis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Ulcerative Proctitis
There are approx. 3+ key companies which are developing the therapies for Ulcerative Proctitis. The companies which have their Ulcerative Proctitis drug candidates in the most advanced stage, i.e. phase I/II include, First Wave Bio.
DelveInsight’s report covers around 3+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Ulcerative Proctitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Ulcerative Proctitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ulcerative Proctitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ulcerative Proctitis drugs.
Ulcerative Proctitis Report Insights
- Ulcerative Proctitis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Ulcerative Proctitis Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Ulcerative Proctitis drugs?
- How many Ulcerative Proctitis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ulcerative Proctitis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Ulcerative Proctitis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Ulcerative Proctitis and their status?
- What are the key designations that have been granted to the emerging drugs?